Evaluation of the Technical Success of IVUS Guided VCF Placement Using the LUMIFI™ With Crux® VCF System

NCT ID: NCT02394912

Last Updated: 2019-07-30

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-06-30
• Study Completion Date: 2016-11-09

Brief Summary

The purpose of this study is to evaluate the safety and effectiveness of the LUMIFI with Crux VCF System for deployment of the Crux VCF. The study will compare the method of Crux VCF deployment using the LUMIFI with Crux VCF System (IVUS guidance) with the historical results of the Crux VCF System (fluoroscopic guidance). The study will include enrollment into a roll in phase consisting of 2 study subjects per site prior to enrollment into the primary treatment phase for primary analyses. The purpose of the roll in phase is to assure compliance with site training on the use of the investigational device and protocol workflow.

Conditions

Pulmonary Embolism; Deep Vein Thrombosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single-arm

Group Type: EXPERIMENTAL

vena cava filter implantation (LUMIFI with Crux VCF System)

Intervention Type: DEVICE

Interventions

vena cava filter implantation (LUMIFI with Crux VCF System)

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Patient is >18 years of age.

2. Patient or their legally authorized representative understands the research nature of the study and is willing and capable of providing informed consent

3. Patient has appropriate femoral vein access

4. Patient at risk for PE and meets at least one of the following sets of conditions:

a. Documented DVT or PE and: i. Inability to anticoagulate the patient due to risk of bleeding such as recent surgery, trauma, intracranial bleed, GI bleed, OR ii. Progression/recurrence of DVT or PE on therapeutic anticoagulation, OR iii. Inability to anticoagulate due to high risk of tumor bleeding, OR iv. Patient unable to safely comply with anticoagulation, OR v. Patient that needs interruption of therapeutic anticoagulation such as at the time of an operation or other procedure.

b. Patient that is high risk for DVT or PE and cannot be safely anticoagulated such as severe multi-trauma patient or patient having procedure with high risk for thromboembolism such as bariatric surgery.

c. Patients with DVT at high risk for PE and free floating iliac or caval thrombosis d. Patients with compromised cardiopulmonary reserve from existing PE with right heart failure/strain who could not tolerate any further insult from new PE

Exclusion Criteria

1. Patient has any one of the following conditions:

1. Thrombus in the iliac veins or the IVC that precludes access to appropriate placement of the Crux Filter

2. Known inadequate venous anatomy to allow insertion or retrieval of the filter from the IVC

3. Known duplicated or left-sided IVC

4. Known IVC transverse diameter at target lower renal ostia > 28mm or < 17mm

5. Known extrinsic compression from abdominal or pelvic mass

6. Known tumor thrombus involving the central venous system

7. Uncontrolled sepsis, infection or persistent bacteremia

8. Patient is at risk for septic pulmonary embolism

9. Patient has an existing implanted filter in the IVC or superior vena cava (SVC) or underwent filter retrieval in previous 60 days.

10. Patient has uncontrollable or active coagulopathy or known uncorrectable bleeding diathesis

11. Patient has a condition that inhibits radiographic visualization of the IVC for post-deployment assessment

2. Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE) or Nitinol (nickel-titanium)

3. Patients unwilling or unable to comply with the protocol

4. Patients with history of or known reaction or sensitivity to contrast agent that cannot be pre-medicated

5. Female patient of childbearing potential who is pregnant (she must have negative pregnancy test within the 48 hours prior to implantation and any retrieval procedure)

6. Patient is participating in another device or drug clinical trial or has participated in such trial in the 30 days prior to enrollment

7. Investigator considers patient to be a poor candidate for the study or believes that the patient may compromise the study, e.g., concomitant conditions (reasons will be documented)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Volcano Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Donald Jacobs, MD

Role: PRINCIPAL_INVESTIGATOR

St. Louis University

Locations

Surgical Care Associates

Louisville, Kentucky, United States

Vascular Access Solutions

Orangeburg, South Carolina, United States

Countries

United States

Other Identifiers

140201

Identifier Type: -

Identifier Source: org_study_id